Journals / Gazi Medical Journal / 2002 / Cilt: 13 - Sayı: 3

Sildenafil sitratin kalp hızı değişkenliği üzerine etkisi

Effects of oral sildenafil citrate (Viagra) on heart rate variability

Pages
117–121
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: SDNN values were not found to be significant when compared with the baseline SDNN. pNN50 was found to be statistically significant when compared with the baseline pNN50 (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To investigate the effects of sildenafil citrate (Viagra) on heart rate variability and to find whether sildenafil citrate is a probable cause of lethal arrhythmias and sudden cardiac death Methods: 50 patients with erectile dysfunction were evaluated with Hoher monitorisation and the heart rate variability was determined over a period before and during oral sildenafil citrate therapy.
📊
Key Findings & Data:Patients have taken 50-mg sildenafil citrate one hour before sexual activity for 3 months.
💡
Conclusion & Impact:Results: SDNN values were not found to be significant when compared with the baseline SDNN. pNN50 was found to be statistically significant when compared with the baseline pNN50 (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To investigate the effects of sildenafil citrate (Viagra) on heart rate variability and to find whether sildenafil citrate is a probable cause of lethal arrhythmias and sudden cardiac death Methods: 50 patients with erectile dysfunction were evaluated with Hoher monitorisation and the heart rate variability was determined over a period before and during oral sildenafil citrate therapy. Patients have taken 50-mg sildenafil citrate one hour before sexual activity for 3 months. After 3 months patients used 50-mg/day-sildenafü citrate for four days before control holler monitorisation. All heart rate variability parameters, such as the standard deviation of the normal -to-normal (NN) intervals (SDNN), the standard deviation of the 5- min average ofNN intervals (SDANN), the square root of squared successive differences in NN intervals (r-MSSD), the percentage ofNN intervals with a cyclic length over 50 ms different from the previous interval (pNNSO), in the time domains studied during 24 hours. Frequency domains such as low frequency (LF) showing sympathetic activity, high frequency (HF) showing parasympathetic activity, and total power (LF/HF ratio) values showing parasympathetic activity were studied during 24 hours. Results: SDNN values were not found to be significant when compared with the baseline SDNN. pNN50 was found to be statistically significant when compared with the baseline pNN50 (p

Özet

Amaç: Sildenafil süratin kalp hızı değişkenliği üzerine etkilerini incelemek, malign aritmi ve ani kardiyak ölümlere yol açıp açmadığını araştırmaktır. Materyal ve Metod: Erektil disfonksiyonu olan 50 hasta çalışmaya alındı. Hastalara sildenafil sitrat tedavisi öncesi ve tedavi sırasında holter monitörizasyonu ile kalp hızı değişkenliği değerleri tesbit edildi. Ortalama 3 ay süresince takip edilen hastalara cinsel ilişkiden 1 saat önce ve günde maksimum 1 kez olmak üzere 50 mg sildenafil sitrat kullanmaları önerildi. 3 ay sonra kontrol hoher monitörizasyonundan 4 gün önceden başlayarak yükleme amacıyla 50 mg/gün sildenafil sitrat kullandırıldı. 4. günün sabahı holter moniterizasyonuna başlanınca ilaç kullandırıldı ve holler sonucunu etkilememesi için 24 saat boyunca cinsel ilişki yasaklandı. 24 saat süreyle kalp hızı değişkenliği değerleri tesbit edildi. Bulgular: 24 saatlik elektrokardiyografi (EKO) kaydındaki tüm normal R-R aralıklarının standart sapması anlamına gelen ve sempatik aktivasyönun göstergesi olan SDNN'nin kontrolü, baseline değeri ile karşılaştırıldığında anlamlı bulunmadı. Tedavi sırasındaki balans (LF/HF) değeri anlamlı olarak düşük bulundu (p

🔖

Cite This Article

TUNÇ, L., BİRİ, H., BOZKIRLI, İ., KARAOĞLAN, Ü., ALKİBAY, T., ALTUNKAN, Ş., KÜPELİ, B. (2022). Sildenafil sitratin kalp hızı değişkenliği üzerine etkisi. Gazi Medical Journal, Cilt: 13 - Sayı: 3, 117–121. https://ajindex.com/articles/520559

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Feldmann HA, Goldstein I, Hatzichristou DG, Krane RJ,and McKinley JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61
  2. Rajfer J, Aronson WJ, Bush PA, Doery FJ, Ignarro LJ.Nitric oxide as a mediator of relaxation of the corpus cavemosum in response to nonadrenergic, noncholinergic neurotrahsmission. N Engl. J Med. 1992; 326: 90-94
  3. Burnett AL. The role of nitric oxide in the physiology of erection. Biol. Reprod 1995; 52: 485-489
  4. Padma-Nathan N, Steers WD, Wicker PA. Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Sildenafil Study Group. Int J Clin Pract. 1998; 52:375-379
  5. A Morales, C Gingell, M Collins, PA Wicker and IH Osterloh. Clinical safety of oral sildenafil citrate in the treatment of erectile dysfunction. Int. J Impot Res. 1998;10: 69-74
  6. Jackson G, Benjamin N, Jackson N, Allen MJ. Effects of sildenafil Citrate on Human Hemodynamics. Am J Cardiol 1999; 83: 13-20
  7. Conti CR, Pepine CJ, Sweeney M. Efficacy and Safety of Sildenafil Citrate in the Treatment of Erectile Dysfunction In-Patients with Ishemic Heart Disease. Am J Cardiol 1999; 83: 29-34
  8. Karasan K, Molgoard H, Wikstrand J, Sjöström L. Heart rate variability in obesity and effect of weight loss. Am J.Cardiol, 1999; 83: 1242-1247
  9. Cowan MJ, Pike K, Burr RL. Effects of gender and age on heart rate variability in healthy individuals and in persons after sudden cardiac arrest. J Electrocardiol 1994;27 (Supp): 1-9
  10. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-830
  11. Greenstein A, Chen J, Miller H, Matzkin H, Villa Ybraf Z. Does severity of ischemic disease correlate with erectile function? Int. J Impot Res. 1997; 9: 123-126
  12. Muller JE, Mittleman A, Maclure M, Sherwood JB, Tofler GH. Triggering myocardial infarction by sexual activity. Low absolute risk and prevention by regular physical exertion. JAMA 1996; 275:1405-1409
  13. Webb DJ^ Boolell M, Muirhead G. Cardiovascular effects of phophodiesterase type 5 inhibition with concomitant nitrate therapy. (Abstr.) Circulation 1998; 98 (suppl 17):637
  14. Carisi A.P, Rohde L.E.P, Ruy SM, Ferlin EL, Leite C,Ribeiro JP. Sympathetic nervous system representation in time and frequency domain in